Purpose of review Microbiota is a major player in the pathogenesis of inflammatory bowel diseases (IBD) and colorectal cancer (CRC). Here, we summarize the key advances achieved in the past 18 months (ending June 2017) toward a better understanding of the role of microbiota in colitis and CRC development.
INTRODUCTION
The intestinal microbiota encompasses microorganisms such as viruses, bacteria and fungi, and this community plays an essential role in modulating host metabolism and immunity [1] . Although the intestinal microbiota is well integrated within host function, a series of mechanisms such as a functional intestinal barrier, mucosal immune surveillance and metabolic crosstalk are in place to maintain homeostasis. Breakdown of these various interactive processes have the potential to dysregulate hostmicrobe interactions, leading to intestinal pathologies such as inflammatory bowel diseases (IBD) and colorectal cancer (CRC) [2, 3] . Recent studies have brought a more detailed understanding of how these regulatory mechanisms ensure optimal integration of host-microbe interactions and help maintain homeostasis. Here we summarize these findings and discuss their impact on IBD and CRC pathogenesis.
BARRIER FUNCTION
Interactions between the intestinal microbiota and the host mucosal compartment are tightly regulated by both a physical barrier and secreted molecules such as mucus, antimicrobial peptides (AMPs) and immunoglobulin A (IgA).
Goblet cells produce various mucins (MUC2, MUC3 and MUC4) that form a polymeric network of glycosylated proteins restraining physical interactions between microbes and the epithelia. MUC2 deficiency in mice leads to overexpression of the goblet cell-derived mucosal defense factor RELM-b, which induces colonic production of the antimicrobial lectins REGIIIb and REGIIIg [4 && ]. REGIIIb predominantly targets Lactobacillus spp., potent producers of beneficial short-chain fatty acids, and oral gavage of murine Lactobacilli spp. isolates reduced RELM-b and REGIIIb levels and ameliorated ]. In contrast, MUC4 appears to promote colitis and tumorigenesis as Muc4 À/À mice are more resistant to dextran sulfate sodium (DSS) colitis and azoxymethane (AOM)/DSS-induced tumorigenesis, which might be because of compensatory upregulation of MUC2 and MUC3 in mutant mice [5] . In addition, intestinal mucin-type O-glycosylation is essential to prevent bacterial intrusion and caspase-1 inflammasome activation, thereby protecting against colitis and CRC [6] .
Intestinal IgA serves as a defense mechanism against enteric microorganisms and toxins. Malik et al. [7 & ] showed that IL-33 modulates the IgAmicrobiota axis to prevent IL-1a-dependent colitis and tumorigenesis. IL-33 synergizes with TGF-b to promote IgA production by B cells [7 & ]. Il-33 À/À mice have reduced colonic IgA, altered microbiota characterized by expansion of the mucolytic Akkermansia spp., and are more susceptible to DSS colitis and AOM/DSS-induced colitis-associated colorectal cancer (CAC) that can be rescued by inhibiting IL-1a [7 & ]. Cohousing with wild type mice or metronidazole depletion of Akkermansia spp. protects Il-33
mice from DSS colitis [7 & ]. Lipocalin 2 (LCN2) is a siderophore-binding antimicrobial protein that limits bacterial iron acquisition. LCN2 is induced by microbiota in a MYD88-dependent manner and prevents formation of a colitogenic microbiota [8] . Lcn2 -/-mice display microbial dysbiosis, characterized by higher bacterial load, increased relative abundance of Bacteroidetes spp. and Proteobacteria spp. and decreased Tenericutes spp. [8] . Cohousing Lcn2 À/À and Il-10 À/À mice exacerbated colitis in the latter [8] . Consistently, Moschen et al. [9 && ] reported that Lcn2 . Aside from these barrier-modulating agents, the intestinal epithelium itself forms a physical barrier against invading microorganisms. Disruption of intestinal epithelial homeostasis leads to colitis and/or tumorigenesis that can be enhanced by microbiota. For example, mice with fucosylation deficiency (Fx À/À ) display loss of Notch activation and downregulation of the Notch target gene Hes1 in the colonic epithelium, accompanied by a progressive increase in gut epithelial permeability [12] . Consistent with the role of Notch in regulating epithelial cell lineage commitment, Fx À/À mice show goblet cell expansion and aberrant crypt proliferation in the colon [12] . Notably, Fx À/À mice sequentially developed colitis, dysplasia and adenocarcinoma, which can be prevented by antibiotic treatment [12] . Similarly, mice with intestinal epithelial cell (IEC)-specific deletion of the IBD susceptibility gene Ptpn11 exhibit impaired goblet cell differentiation in the colon and dysbiotic microbiota that drive spontaneous colitis development [13] .
At the basal side, the intestinal epithelium is connected to the basement membrane via hemidesmosomes wherever plectin links a6b4 integrin to cytoplasmic keratin filaments. Mice with IECspecific deletion of a6 integrin developed spontaneous colitis and adenocarcinoma [14] . Inflammation, which can be attenuated by antibiotic treatment, is driven by epithelium detachment-induced caspase-1 inflammasome activation and IL-18 secretion by
KEY POINTS
Proper mucosal barrier function maintained by secreted molecules (mucin, IgA, AMPs, etc.) and structural components (epithelium, hemidesmosome, keratin, etc.) prevents microbial invasion and CAC.
Aberrant innate signaling and immune responses foster development of a dysbiotic microbiota that could aggravate inflammation and tumorigenesis.
Metabolic interactions between host and microbiota via tryptophan, bile acids and vitamin A critically impact colitis and CRC development.
MiRNAs emerge as important mediators of hostmicrobiota crosstalk.
Alistipes finegoldii, A. muciniphila, A. parvulum and P. anaerobius are newly identified microbial drivers of colitis and/or CRC.
Novel insights into microbiome in colitis and colorectal cancer Yang and Jobin epithelial cells, whereas tumorigenesis depends on IL-1 signaling and adaptive immunity [14] . Liu et al. [15] showed that mice haplodeficient in keratin 8, a major intermediate filament protein in the intestinal epithelia, were more susceptible to DSS colitis and more prone to AOM/DSS-induced CAC, which could be attenuated by TLR4 inhibition and antibiotic treatment, respectively. Together, the data suggest that compromised structural integrity of the epithelia increases the risk for inflammation and tumor development.
Tumor sites have impaired barrier that can further enhance carcinogenesis. One mechanism recently demonstrated by Peuker et al. [16 & ] is that intruding bacteria activate toll-like receptor (TLR)-dependent calcineurin/nuclear factor of activated T cells signaling in neoplastic cells, resulting in upregulation of stem cell-associated genes (e.g. Cd44v6, Lgr5, Olfm4 and Dclk1) and thus, tumor stem cell function.
INNATE SENSORS AND IMMUNE SIGNALING
The host recognizes microbial structures and components via pattern-recognition receptors (PPRs) such as TLRs, nod-like receptors (NLRs) and RIG-Ilike receptors (RLRs) expressed by a variety of immune and nonimmune cells.
Increased expression of TLR4 has been reported in the epithelium of patients with IBD, CAC and sporadic colon cancers. Overexpression of TLR4 in intestinal epithelial cells results in disrupted barrier function and dysbiotic microbiota characterized by increased abundance of Lachnospiraceae [17] . This altered microbiota is proinflammatory as cohoused wild type mice exhibit increased sensitivity to DSS colitis [17] .
NOD2 is an IBD susceptibility gene and has been linked to human CRC. Udden et al. [18 & ] recently demonstrated that NOD2 negatively regulates TLR/ NF-kB signaling to suppress tumorigenesis. Cohousing and microbiota transfer experiments suggest that the microbiota enhances colitis but appears not to be the major driver of the increased CRC susceptibility observed in Nod2 À/À mice compared with wild type mice [18 & ]. Mechanistically, NOD2 induces IRF4 that interacts with MYD88 and TRAF6 to suppress TLR/NF-kB signaling in myeloid cells [18 & ]. Expression of NLRC3 is reduced in CRC tumors. Karki et al. [19] demonstrated that NLRC3 suppresses tumorigenesis by inhibiting PI3K-AKT-mTOR signaling in Apc min/þ mice and AOM/DSS-treated wild type mice. At the molecular level, NLRC3 interacts with PI3K to block AKT activation and binds to TRAF6 to attenuate TLR/NF-kB and mTOR activation [19, 20] .
Activation of the NLRP6 inflammasome is modulated by microbiota-derived metabolites such as taurine and histamine, and regulates IL-18 and AMP production to maintain gut homeostasis [21] [24] found that RIG-I expression was downregulated in human CAC tumor sites and that Rig-I À/À mice had reduced levels of intestinal IgA and REGIIIg, concurrent with disturbance in microbiota composition, compared with wild type mice. Rig-I À/À mice are more susceptible to AOM/DSS-induced tumorigenesis, which can be partially attenuated by antibiotic treatment [24] , suggesting that bacteria-dependent and bacteria -independent mechanisms contribute to the protective role of RIG-I against CAC.
IRAK-M is a negative regulator of TLR/NK-kB signaling and found to be upregulated in IBD and CRC patients [25, 26] . Irak-m À/À mice showed enhanced colitis but reduced tumorigenesis following AOM/DSS treatment [25] . Cohousing experiments suggest that inflammation, but not tumorigenesis, is microbiota-dependent in Irakm À/À mice [25] . TLR and WNT activation in tumor cells drive IRAK-M expression, which promotes tumorigenesis by preventing STAT3 proteasomal degradation [25] . Another study confirmed the protective role of IRAK-M against AOM/DSS-induced tumorigenesis, although the authors reported resistance to DSS colitis and attenuation of intestinal microbial translocation in Irak-m À/À mice [26] . NEMO is a component of the IKB kinase complex that activates NF-kB by phosphorylating IkB proteins. Mice lacking NEMO in IECs develop spontaneous colitis in SPF but not germ-free conditions, supporting the critical role of microbiota [27] . Further investigation reveals that NEMO prevents Paneth cell and colonic epithelial cell death by activating NF-kB and inhibiting RIPK1 kinase activity, respectively [27] .
METABOLISM
CARD9 is an IBD susceptibility gene involved in regulation of PPR-induced inflammatory responses and inflammasome activities. Card9 À/À mice have altered microbiota characterized by decreased abundance of Adlercreutzia spp., Actinobacteria (phylum) and Lactobacillus reuteri, resulting in defective tryptophan metabolism into indole derivatives such as indole-3-acetic acid [28 && ]. Therefore, these mice fail to activate aryl hydrocarbon receptor (AHR) to induce IL-22 expression [28 && ]. Inoculating Card9 À/À mice with tryptophan-metabolizing Lactobacillus spp. strains or treatment with an AHR agonist attenuated DSS colitis, suggesting CARD9 regulates the microbiota-tryptophan-AHR-IL-22 axis to affect colitis susceptibility [28 && ]. Importantly, AHR activity and tryptophan metabolites are found to be reduced in IBD patients [28 && ]. Bile acids are end products of hepatic cholesterol catabolism and secreted into the gut lumen where they are transformed by bacteria into secondary bile acids including lithocholic acid and deoxycholic acid (DCA). Recent studies demonstrated bile acids can affect microbiota and development of colitis and CRC. For example, IEC-derived SIRT1, a NADþ-dependent protein deacetylase downregulated in ulcerative colitis patients, prevents age-dependent reduction of Bacilli/Lactobacillus partially via regulating bile acid metabolism [29] . In addition, DCA administration accelerates tumorigenesis by inducing microbiota dysbiosis and inflammation in Apc Vitamin A metabolite all-trans-retinoic acid (atRA) is mainly produced by the epithelium and plays important physiological functions. In human sporadic CRC, ulcerative colitis and ulcerative colitis -associated CRC, the atRNA-synthesizing enzyme ALDH1 is significantly decreased whereas the atRNA-catabolizing enzyme CYP26A1 is increased, suggestive of common atRA deficiency in these pathologies [ ]. Activation of inflammatory responses appears to play a role in microbial regulation of miRNAs. F. nucleatum induces miR-21 in CRC cells by activating TLR4/MYD88/NF-kB signaling, a process responsible for the enhanced CRC cell proliferation and invasion following infection [34 & ]. Given that inflammatory responses are commonly associated with bacterial infection that likely occurs frequently in IBD and CAC wherever barrier function is impaired, microbe-miRNA reciprocal modulation might be a key component of the disease cause.
SPECIFIC MICROBES
Enterotoxigenic Bacteroides fragilis (ETBF), pksþ adherent invasive E. coli and F. nulceatum have been shown to possess colitogenic and/or carcinogenic activities [2, 3] . Duration of ETBF colonization positively correlates with tumorigenesis in Min ApcD716 mice, suggesting that early ETBF acquisition is potentially carcinogenic and that depletion of this bacterium could prevent cancer [35] . Abed et al. [36] demonstrated that F. nucleatum preferentially accumulates in colorectal adenocarcinomas via Fap2/ Gal-GalNAc interaction. However, Tomkovich et al. [37] 
CONCLUSION
These studies highlight the rapid pace of discoveries made in the field of microbiota and intestinal pathologies and specifically underscore the critical importance of proper integration of host-microbiota crosstalk. The signaling events initiated by host-microorganism communication through either structural proteins or small molecules offer new perspectives for therapeutic intervention. For example, microbial components implicated in barrier function, metabolism and immune modulation could serve as therapeutic targets for management of inflammation and carcinogenesis. Although great progress has been made in this field of research, a number of challenges lie ahead. For example, big gap of knowledge exists about microbial interspecies communication and how this affects host homeostasis. As IBD and CRC are diseases associated with not only breakdown of host-microbe interaction, but also likely defective polymicrobial interplay, it is essential to decipher this complex communication network. Moreover, the literature on microbiota and IBD/ CRC pathology is vastly dominated by research examining roles of bacteria, with little attention to other members of the community (viruses, fungi, etc). Although links have been made regarding the implication of these microorganisms in intestinal pathology [40] , more research is needed to understand their functions and disease-modulating mechanisms, particularly trans-kingdom interactions. We expect that future studies will provide a comprehensive view of how the microbiota and its complex constituents interact with the host to influence health and disease.
